Age-Specific Profiles of Antibody Responses against Respiratory Syncytial Virus Infection
Respiratory syncytial virus (RSV) is one of the most prevalent causative agents of lower respiratory tract infections worldwide, especially in infants around 3 to 4 months old. Infants at such a young age have maternally-transferred passive antibodies against RSV but do not have active immune system...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-02-01
|
Series: | EBioMedicine |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S235239641730018X |
id |
doaj-b40c38bc15cb4dbab430c322580a0d67 |
---|---|
record_format |
Article |
spelling |
doaj-b40c38bc15cb4dbab430c322580a0d672020-11-25T00:13:53ZengElsevierEBioMedicine2352-39642017-02-0116C12413510.1016/j.ebiom.2017.01.014Age-Specific Profiles of Antibody Responses against Respiratory Syncytial Virus InfectionNao Jounai0Megumi Yoshioka1Miyuki Tozuka2Kazue Inoue3Tatsuya Oka4Kazuki Miyaji5Katsuyasu Ishida6Naoki Kawai7Hideyuki Ikematsu8Chiaki Kawakami9Hiroyuki Shimizu10Masaaki Mori11Ken J. Ishii12Fumihiko Takeshita13Kitasato Daiichi Sankyo Vaccine Co., Ltd., 1-16-13 Kitakasai, Edogawa-ku, Tokyo 134-8630, JapanKitasato Daiichi Sankyo Vaccine Co., Ltd., 1-16-13 Kitakasai, Edogawa-ku, Tokyo 134-8630, JapanKitasato Daiichi Sankyo Vaccine Co., Ltd., 1-16-13 Kitakasai, Edogawa-ku, Tokyo 134-8630, JapanKitasato Daiichi Sankyo Vaccine Co., Ltd., 1-16-13 Kitakasai, Edogawa-ku, Tokyo 134-8630, JapanKitasato Daiichi Sankyo Vaccine Co., Ltd., 1-16-13 Kitakasai, Edogawa-ku, Tokyo 134-8630, JapanKitasato Daiichi Sankyo Vaccine Co., Ltd., 1-16-13 Kitakasai, Edogawa-ku, Tokyo 134-8630, JapanDaiichi Sankyo Co., Ltd., 3-5-1 Nihonbashi Honcho, Chuo-ku, Tokyo 103-8426, JapanJapan Physicians Association, 2-5 Kanda Surugadai, Chiyoda-ku, Tokyo 101-0062, JapanJapan Physicians Association, 2-5 Kanda Surugadai, Chiyoda-ku, Tokyo 101-0062, JapanDepartment of Pediatrics, Yokosuka Kyosai Hospital, 1-16 Yonegahamadori, Yokosuka, Kanagawa 238-8558, JapanChildren's Medical Center, Yokohama City University Medical Center, 4-57 Urafune, Minami-ku, Yokohama, Kanagawa 232-0024, JapanDepartment of Lifetime Clinical Immunology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, JapanLaboratory of Adjuvant Innovation, National Institutes of Biomedical Innovation, Health and Nutrition, 7-6-8 Saito-Asagi, Ibaraki City, Osaka 567-0085, JapanDaiichi Sankyo Co., Ltd., 3-5-1 Nihonbashi Honcho, Chuo-ku, Tokyo 103-8426, JapanRespiratory syncytial virus (RSV) is one of the most prevalent causative agents of lower respiratory tract infections worldwide, especially in infants around 3 to 4 months old. Infants at such a young age have maternally-transferred passive antibodies against RSV but do not have active immune systems efficient enough for the control of RSV infection. In order to elucidate age-specific profiles of immune responses against RSV protection, antibody responses were examined by using blood samples in both acute and convalescent phases obtained from child patients and adult patients. In addition to the serum neutralization activity, antibody responses to the RSV fusion protein (F protein) were dissected by analyzing levels of total IgG, IgG subclasses, the binding stability, and the levels of antibody for the neutralization epitopes. It was suggested that children's antibody responses against RSV are matured over months and years in at least 5 stages based on 1) levels of the neutralization titer and IgG3 for F protein in the convalescent phase, 2) geometric mean ratios of the neutralization titers and levels of IgG1 and IgG2 for F protein in the convalescent phase compared to those levels in the acute phase, 3) the affinity maturation of IgG for F protein and the cross reactivity of IgG for RSV glycoproteins of groups A and B, 4) levels of neutralization epitope-specific IgG, and 5) augmentation of overall antibody responses due to repetitive RSV infection.http://www.sciencedirect.com/science/article/pii/S235239641730018XRSVF proteinIgG3Palivizumab-like neutralization antibody |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Nao Jounai Megumi Yoshioka Miyuki Tozuka Kazue Inoue Tatsuya Oka Kazuki Miyaji Katsuyasu Ishida Naoki Kawai Hideyuki Ikematsu Chiaki Kawakami Hiroyuki Shimizu Masaaki Mori Ken J. Ishii Fumihiko Takeshita |
spellingShingle |
Nao Jounai Megumi Yoshioka Miyuki Tozuka Kazue Inoue Tatsuya Oka Kazuki Miyaji Katsuyasu Ishida Naoki Kawai Hideyuki Ikematsu Chiaki Kawakami Hiroyuki Shimizu Masaaki Mori Ken J. Ishii Fumihiko Takeshita Age-Specific Profiles of Antibody Responses against Respiratory Syncytial Virus Infection EBioMedicine RSV F protein IgG3 Palivizumab-like neutralization antibody |
author_facet |
Nao Jounai Megumi Yoshioka Miyuki Tozuka Kazue Inoue Tatsuya Oka Kazuki Miyaji Katsuyasu Ishida Naoki Kawai Hideyuki Ikematsu Chiaki Kawakami Hiroyuki Shimizu Masaaki Mori Ken J. Ishii Fumihiko Takeshita |
author_sort |
Nao Jounai |
title |
Age-Specific Profiles of Antibody Responses against Respiratory Syncytial Virus Infection |
title_short |
Age-Specific Profiles of Antibody Responses against Respiratory Syncytial Virus Infection |
title_full |
Age-Specific Profiles of Antibody Responses against Respiratory Syncytial Virus Infection |
title_fullStr |
Age-Specific Profiles of Antibody Responses against Respiratory Syncytial Virus Infection |
title_full_unstemmed |
Age-Specific Profiles of Antibody Responses against Respiratory Syncytial Virus Infection |
title_sort |
age-specific profiles of antibody responses against respiratory syncytial virus infection |
publisher |
Elsevier |
series |
EBioMedicine |
issn |
2352-3964 |
publishDate |
2017-02-01 |
description |
Respiratory syncytial virus (RSV) is one of the most prevalent causative agents of lower respiratory tract infections worldwide, especially in infants around 3 to 4 months old. Infants at such a young age have maternally-transferred passive antibodies against RSV but do not have active immune systems efficient enough for the control of RSV infection. In order to elucidate age-specific profiles of immune responses against RSV protection, antibody responses were examined by using blood samples in both acute and convalescent phases obtained from child patients and adult patients. In addition to the serum neutralization activity, antibody responses to the RSV fusion protein (F protein) were dissected by analyzing levels of total IgG, IgG subclasses, the binding stability, and the levels of antibody for the neutralization epitopes. It was suggested that children's antibody responses against RSV are matured over months and years in at least 5 stages based on 1) levels of the neutralization titer and IgG3 for F protein in the convalescent phase, 2) geometric mean ratios of the neutralization titers and levels of IgG1 and IgG2 for F protein in the convalescent phase compared to those levels in the acute phase, 3) the affinity maturation of IgG for F protein and the cross reactivity of IgG for RSV glycoproteins of groups A and B, 4) levels of neutralization epitope-specific IgG, and 5) augmentation of overall antibody responses due to repetitive RSV infection. |
topic |
RSV F protein IgG3 Palivizumab-like neutralization antibody |
url |
http://www.sciencedirect.com/science/article/pii/S235239641730018X |
work_keys_str_mv |
AT naojounai agespecificprofilesofantibodyresponsesagainstrespiratorysyncytialvirusinfection AT megumiyoshioka agespecificprofilesofantibodyresponsesagainstrespiratorysyncytialvirusinfection AT miyukitozuka agespecificprofilesofantibodyresponsesagainstrespiratorysyncytialvirusinfection AT kazueinoue agespecificprofilesofantibodyresponsesagainstrespiratorysyncytialvirusinfection AT tatsuyaoka agespecificprofilesofantibodyresponsesagainstrespiratorysyncytialvirusinfection AT kazukimiyaji agespecificprofilesofantibodyresponsesagainstrespiratorysyncytialvirusinfection AT katsuyasuishida agespecificprofilesofantibodyresponsesagainstrespiratorysyncytialvirusinfection AT naokikawai agespecificprofilesofantibodyresponsesagainstrespiratorysyncytialvirusinfection AT hideyukiikematsu agespecificprofilesofantibodyresponsesagainstrespiratorysyncytialvirusinfection AT chiakikawakami agespecificprofilesofantibodyresponsesagainstrespiratorysyncytialvirusinfection AT hiroyukishimizu agespecificprofilesofantibodyresponsesagainstrespiratorysyncytialvirusinfection AT masaakimori agespecificprofilesofantibodyresponsesagainstrespiratorysyncytialvirusinfection AT kenjishii agespecificprofilesofantibodyresponsesagainstrespiratorysyncytialvirusinfection AT fumihikotakeshita agespecificprofilesofantibodyresponsesagainstrespiratorysyncytialvirusinfection |
_version_ |
1725392555724505088 |